Discovery of antibodies and cognate surface targets for ovarian cancer by surface profiling

[HTML] nih.gov

[HTML][HTML] Targeted radiopharmaceuticals: an underexplored strategy for ovarian cancer

M Crabbé, T Opsomer, K Vermeulen, M Ooms… - …, 2024 - pmc.ncbi.nlm.nih.gov
Ovarian cancer is the most common gynecological malignancy worldwide with the highest
mortality. This low survival rate can be attributed to the fact that symptoms arise only at an …
相关文章 所有 3 个版本

First-Generation Radiolabeled Cyclic Peptides for Molecular Imaging of Platelet-Derived Growth Factor Receptor α

S Pike, M Wuest, A Lopez-Campistrous… - Molecular …, 2024 - ACS Publications
Occult nodal spread and metastatic disease require longstanding imaging and biochemical
assessments for thyroid cancer, a disease that has a propensity for diffuse, small-volume …
相关文章 所有 3 个版本

Histone Lysine Lactylation (Kla)‐induced BCAM Promotes OSCC Progression and Cis‐Platinum Resistance

G Huang, S Chen, J He, H Li, Z Ma, GP Lubamba… - Oral Diseases - Wiley Online Library
ABSTRACT Objective Histone lysine lactylation (Kla) plays a vital role in cancer progression.
However, the prognostic value of histone Kla in oral squamous cell carcinoma (OSCC) …
相关文章 所有 2 个版本
[PDF] uni-marburg.de

Role of BCAM in ovarian cancer metastasis

S Sivakumar - 2023 - archiv.ub.uni-marburg.de
Ovarian cancer (OC) is one of the deadliest gynecological malignancies due to its early and
wide-spread peritoneal dissemination, with the omentum being the preferred site of …
相关文章 所有 2 个版本

Therapeutic potential of cis-targeting bispecific antibodies

RC Oslund, PM Holland, SA Lesley, OO Fadeyi - Cell Chemical Biology, 2024 - cell.com
The growing clinical success of bispecific antibodies (bsAbs) has led to rapid interest in
leveraging dual targeting in order to generate novel modes of therapeutic action beyond …
相关文章 所有 4 个版本